Dimethaid creates, fills scientific advisory board
2005-09-19 08:58 ET - News Release
Mr. Peter Block reports
DIMETHAID CREATES SCIENTIFIC ADVISORY BOARD -- INTERNATIONALLY RECOGNIZED EXPERTS TO SUPPORT COMPANY'S DRUG DEVELOPMENT
Dimethaid Research Inc. has created a scientific advisory board and made its first three appointments.
The scientific advisory board will provide Dimethaid senior management with scientific, medical and strategic advice on Dimethaid's drug development plans and specific issues relating to its business.
Joining the body will be:
Dr. Stefan Meuer, a German immunologist who is chairman of the International Committee of the Federation of Clinical Immunology Societies;
Dr. Lee Simon, an American rheumatologist and Harvard associate professor who previously was a director at the United States Food and Drug Administration (FDA); and
Dr. Rolf Zinkernagel, a Swiss Nobel Prize-winning immunologist.
"We are pleased that these three distinguished scientists have agreed to join our scientific advisory board," said Dr. Henrich Guntermann, president and chief executive officer of Dimethaid Research. "As we move forward with our drug development plans, we will undoubtedly benefit from the advice and guidance of such an esteemed group of experts."
Dr. Meuer, MD
Dr. Meuer is currently a director of the Institute of Immunology at the University Hospital in Heidelberg, Germany. He has a long and distinguished career in medical research and has authored/co-authored over 150 publications in the field of immunology. Dr. Meuer is:
a member of the German Scientific Council Committee, Medicine, Evaluation and Quantification;
chairman of the board, Bio-Region Rhein Neckar; and
chairman, International Committee of the Federation of Clinical Immunology Societies.
He received his medical degree from Johannes-Gutenberg-Universitat in Mainz, Germany.
Dr. Simon, MD
Dr. Simon is currently an associate clinical professor at Harvard Medical School and head regulatory consultant with MEDACorp management consulting group, which offers strategic advice to leading life sciences and health care companies. Previously, Dr. Simon was with the FDA where he was the division director of the arthritis, analgesic and ophthalmologic drug product division. Prior to his tenure at the FDA, Dr. Simon was director of Rheumatology Clinical Research and as associate chief of medicine at Beth Israel Deaconess Medical Center in Boston, Mass. Dr. Simon attended Loyola College and received his medical degree from the University of Maryland School of Medicine.
Dr. Zinkernagel, MD, PhD
Dr. Zinkernagel is a professor, department of pathology, at the University of Zurich and has been the co-head of the Institute of Experimental Immunology in Zurich, Switzerland, since 1992. Dr. Zinkernagel is an internationally recognized immunologist who has received more than 25 awards for his work during the past two decades, including the 1996 Nobel Prize in medicine for discoveries concerning the specificity of the cell-mediated immune defence. He received a PhD from the Australian National University and a medical degree from the University of Basel in Switzerland.
We seek Safe Harbor. |
